JP2022502015A5 - - Google Patents

Info

Publication number
JP2022502015A5
JP2022502015A5 JP2021514551A JP2021514551A JP2022502015A5 JP 2022502015 A5 JP2022502015 A5 JP 2022502015A5 JP 2021514551 A JP2021514551 A JP 2021514551A JP 2021514551 A JP2021514551 A JP 2021514551A JP 2022502015 A5 JP2022502015 A5 JP 2022502015A5
Authority
JP
Japan
Prior art keywords
peptide
cancer
seq
fragment
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021514551A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502015A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/074898 external-priority patent/WO2020058285A1/en
Publication of JP2022502015A publication Critical patent/JP2022502015A/ja
Publication of JP2022502015A5 publication Critical patent/JP2022502015A5/ja
Ceased legal-status Critical Current

Links

JP2021514551A 2018-09-17 2019-09-17 がんに対する免疫療法で使用するためのb*44拘束性ペプチドおよび関連方法 Ceased JP2022502015A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862732300P 2018-09-17 2018-09-17
DE102018122623.3 2018-09-17
US62/732,300 2018-09-17
DE102018122623 2018-09-17
PCT/EP2019/074898 WO2020058285A1 (en) 2018-09-17 2019-09-17 B*44 restricted peptides for use in immunotherapy against cancers and related methods

Publications (2)

Publication Number Publication Date
JP2022502015A JP2022502015A (ja) 2022-01-11
JP2022502015A5 true JP2022502015A5 (enExample) 2022-09-29

Family

ID=67999633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514551A Ceased JP2022502015A (ja) 2018-09-17 2019-09-17 がんに対する免疫療法で使用するためのb*44拘束性ペプチドおよび関連方法

Country Status (19)

Country Link
US (18) US11945850B2 (enExample)
EP (1) EP3853243A1 (enExample)
JP (1) JP2022502015A (enExample)
KR (1) KR20210061340A (enExample)
CN (1) CN112789285A (enExample)
AU (1) AU2019344565B2 (enExample)
BR (1) BR112021004170A2 (enExample)
CA (1) CA3108578A1 (enExample)
CL (1) CL2021000649A1 (enExample)
CO (1) CO2021004270A2 (enExample)
CR (1) CR20210140A (enExample)
IL (2) IL309716A (enExample)
MA (1) MA53641A (enExample)
MX (1) MX2021003067A (enExample)
PE (1) PE20211642A1 (enExample)
PH (1) PH12021550346A1 (enExample)
SG (1) SG11202101924QA (enExample)
TW (1) TW202028224A (enExample)
WO (1) WO2020058285A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
PE20191248A1 (es) 2017-01-27 2019-09-18 Immatics Biotechnologies Gmbh Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer
EA201991444A1 (ru) * 2017-01-27 2019-12-30 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
CN119080881A (zh) 2017-07-07 2024-12-06 伊玛提克斯生物技术有限公司 用于肺癌(包括nsclc、sclc和其他癌症)免疫治疗的新型肽和肽组合物
WO2019007974A1 (en) 2017-07-07 2019-01-10 Immatics Biotechnologies Gmbh NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods
EP4091627A1 (en) * 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
WO2024178334A1 (en) * 2023-02-24 2024-08-29 The Children's Hospital Of Philadelphia Improved phox2b pc-car generation based on structure and saturation mutagenesis

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
DK171727B1 (da) 1978-12-22 1997-04-14 Biogen Inc Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
DE69420137T2 (de) 1993-06-03 1999-12-23 Therapeutic Antibodies, Inc. Herstellung von antikörperfragmenten
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5977300A (en) 1994-06-03 1999-11-02 Ludwig Institute Of Cancer Research Isolated nonapeptide which bind to HLA-B44 molecules and the uses thereof
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU2001229681A1 (en) 2000-01-20 2001-07-31 Ludwig Institute For Cancer Research Mage antigenic peptides which bind hla-b35 and hla-b44
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
AU7524601A (en) 2000-06-05 2001-12-17 Sunol Molecular Corp T cell receptor fusions and conjugates and methods of use thereof
US20030171275A1 (en) 2000-12-20 2003-09-11 Baughn Mariah R. Transporters and ion channels
US20030087245A1 (en) 2001-01-24 2003-05-08 Eos Biotechnology, Inc. Uses of PBH1 in the diagnosis and therapeutic treatment of prostate cancer
AU2002322280A1 (en) 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (en) 2002-02-20 2006-04-26 Dyax Corp MHC-PEPTIDE COMPLEX BINDING LIGANDS
US7311914B2 (en) 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
AU2003276403B2 (en) 2002-11-09 2010-04-15 Adaptimmune Limited T cell receptor display
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US7348007B2 (en) 2004-02-09 2008-03-25 Ludwig Institute For Cancer Research Mage C2 antigenic peptides and uses thereof
US7883858B2 (en) 2005-01-27 2011-02-08 Institute For Systems Biology Methods for identifying and monitoring drug side effects
EP1806358B1 (en) 2005-09-05 2010-03-17 Immatics Biotechnologies GmbH Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
WO2007053570A2 (en) 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. A polypeptide complex of trpm8 and calmodulin and its uses thereof
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
KR102095670B1 (ko) 2010-05-14 2020-03-31 더 제너럴 하스피톨 코포레이션 종양 특이적 신생항원을 확인하는 조성물 및 방법
WO2012056407A1 (en) 2010-10-26 2012-05-03 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2012094744A1 (en) 2011-01-11 2012-07-19 University Health Network Prognostic signature for oral squamous cell carcinoma
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
EP2917388B1 (en) 2012-11-08 2016-10-05 Roche Diagnostics GmbH Nucleic acids encoding chimeric polypeptides for library screening
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
EP4636401A2 (en) 2014-12-19 2025-10-22 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
US11130798B2 (en) 2015-05-19 2021-09-28 La Jolla Institute For Allergy And Immunology Human APOB100 epitopes, methods and uses for modulating inflammatory responses, and treating adverse cardiovascular events, disease and atherosclerosis
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201520541D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
IL265479B (en) * 2016-09-21 2022-09-01 Amal Therapeutics Sa A fusion containing a cell-penetrating peptide, a multiple epitope, and a peptide tlr agonist for cancer therapy
AU2018226566B2 (en) * 2017-03-03 2025-01-23 Treos Bio Limited Population-based immunogenic peptide identification platform
US11427614B2 (en) 2017-04-10 2022-08-30 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
WO2018189152A2 (en) 2017-04-10 2018-10-18 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
WO2019007974A1 (en) 2017-07-07 2019-01-10 Immatics Biotechnologies Gmbh NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods

Similar Documents

Publication Publication Date Title
JP2024041841A5 (enExample)
JP2024099580A5 (enExample)
JP2021535900A5 (enExample)
US12338272B2 (en) High avidity antigen recognizing constructs
JP2019511214A5 (enExample)
JP2022502358A5 (enExample)
JP2021514178A5 (enExample)
JP2021168652A5 (enExample)
JP2019502360A5 (enExample)
JP2020516681A5 (enExample)
JP2021528046A5 (enExample)
JP2019516663A5 (enExample)
JP2019510465A5 (enExample)
JP2020191862A5 (enExample)
JP2020182458A5 (enExample)
JP2019506838A5 (enExample)
RU2017137142A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
JP2018510628A5 (enExample)
JP2018536383A5 (enExample)
JP2018529320A5 (enExample)
JP2018520653A5 (enExample)
JP2018518937A5 (enExample)
JP2018509135A5 (enExample)
JP2018519243A5 (enExample)
JP2018511321A5 (enExample)